ABSTRACT
Treatment of anaemia is a very important aspect in the management of cancer patients. In order to carry out a consensus process about the use of erythropoietic stimulating agents (ESAs) in cancer patients, the Spanish Society of Medical Oncology (SEOM) elaborated a working group which coordinated a panel of medical oncology specialists. This working group has reviewed the main issues about the use of ESAs. In addition a consensus meeting was held in Madrid on 25 April 2007. The following conclusions were made: Since ESA treatment increases the haemoglobin (Hb) level and decreases the red blood cell (RBC) transfusion requirements, ESAs should be used within the approved indications in patients undergoing chemotherapy treatment, beginning at a Hb level below 11 g/dl and maintaining it around 12 g/dl, with iron supplements if necessary. Neither increasing the ESA dose in nonresponders nor the use of ESAs in the treatment of chronic cancer-related anaemia is recommended (AU)
No disponible
Subject(s)
Humans , Male , Female , Anemia/complications , Anemia/drug therapy , Hematinics/metabolism , Hematinics/therapeutic use , Medical Oncology/methods , Neoplasms/complications , Antineoplastic Agents/adverse effects , Antineoplastic Agents/therapeutic use , Blood Transfusion , Chronic Disease/drug therapy , Clinical Trials as Topic/methods , Clinical Trials as Topic , Erythrocytes/metabolism , Hemoglobins/metabolism , Iron/metabolism , Spain/epidemiologyABSTRACT
Neutropenia is a common complication of cancer chemotherapy. Colony-stimulating factors (CSF) may be used to avoid neutropenia-associated complications. The Spanish Society of Medical Oncology (SEOM) recently constituted a working group to review the main issues concerning the use of CSF and carried out a consensus process about the use of CSF in cancer patients, held in Madrid on 26 May 2006. The group concluded the following recommendations: prophylactic use of CSF is recommended when a rate of febrile neutropenia (FN) higher than 20% is expected without the use of CSF or when additional risk factors for neutropenia exist; therapeutic use of CSF is recommended in order to treat FN episodes but not to treat afebrile neutropenic episodes. In addition, the use of CSF is considered effective when used to mobilise stem cells before high-dose chemotherapy and when used for chemotherapy schedule optimisation in dose-dense and in dose-intense regimens (AU)
Subject(s)
Humans , Male , Female , Colony-Stimulating Factors/therapeutic use , Neoplasms/complications , Neutropenia/epidemiology , Neutropenia/prevention & control , Neutropenia/etiology , Neutropenia/urine , Spain/epidemiology , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Drug Therapy, Combination/methods , Drug Therapy, CombinationSubject(s)
Antineoplastic Agents/adverse effects , Lung Diseases, Interstitial/chemically induced , Lung Diseases, Interstitial/pathology , Organoplatinum Compounds/adverse effects , Adenocarcinoma/drug therapy , Adrenal Cortex Hormones/therapeutic use , Aged , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Colonic Neoplasms/drug therapy , Female , Fluorouracil/adverse effects , Humans , Leucovorin/adverse effects , Lung Diseases, Interstitial/drug therapy , Male , Middle Aged , OxaliplatinABSTRACT
Presentation of one case of bilateral renal adenocarcinoma in a 63-year old female patient, undergoing surgical therapy by means of right radical nephrectomy and left partial nephrectomy. Within 6 months, the patient presented pulmonary metastasis and normocytic anaemia associated to paraneoplastic syndrome. After initiating treatment with Interleukin-2 in intravenous continuous infusion, both pulmonary metastasis and anaemia showed evidence of partial regression.
